Short answer
Merck & Co. (MRK) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.2). Q1 2026 earnings press release issued April 30, 2026, with results in Exhibit 99.1.
Merck & Co. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 earnings press release issued April 30, 2026, with results in Exhibit 99.1
- Supplemental information in Exhibit 99.2, providing additional investor detail
- Earnings materials furnished, not filed under Exchange Act Section 18
- Materials excluded from automatic incorporation into other SEC filings unless specifically referenced
Item EX-99.1 · Exhibit EX-99.2
- Q1 sales $16.3B, up 5% and 3% ex-FX, led by KEYTRUDA/KEYTRUDA QLEX $8.0B and WINREVAIR $525M
- GAAP loss per share $1.72 and non-GAAP loss per share $1.28, including Cidara acquisition charge of $3.62 per share
- KEYTRUDA/KEYTRUDA QLEX grew 12%, while GARDASIL declined 19% and JANUVIA/JANUMET declined 28%, highlighting portfolio concentration and erosion
- 2026 outlook raised to sales $65.8B-$67.0B and non-GAAP EPS $5.04-$5.16, excluding Terns acquisition impact
- Terns acquisition expected in May, adding Phase 1/2 TERN-701 and triggering approximately $5.8B one-time charge or $2.35 per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Merck & Co. 8-K filings
Get the next MRK 8-K as it lands
Follow MRK for push alerts, or ask the research agent what this filing means.